7 news items
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
authorization were fulfilled in May 2022. The approved indications in the European Union are: (1) for the treatment of adult patients with previously
Takeda Gets Positive CHMP Opinion For Recombinant ADAMTS13 In Congenital Thrombotic Thrombocytopenic Purpura
TAK
31 May 24
a Mortality Rate of >90%1,2If Approved in the European Union, rADAMTS13 Will Be the First and Only Recombinant
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK
31 May 24
in the European Union, rADAMTS13 Will Be the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for cTTP
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
SNY
TAK
15 May 24
in Indonesia, Brazil, the European Union (EU), Iceland, the U.K., Norway, and Lichtenstein.
Developed by Takeda, it is a live-attenuated
Takeda Receives Positive CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless
lrqc6xljkgu5q9crlvoci5klpcraodzcjo9h5m3zamj8cjs0g3bl
TAK
26 Apr 24
in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over
49zbv4yuh371exbwn428hyvtw5u4yr8jjvggylhb4fl03k 3t
TAK
18 Apr 24
Vedolizumab SC has been granted marketing authorization in the United States, European Union and more than 50 countries. Vedolizumab IV has been
- Prev
- 1
- Next